Sep 24 2024
Narcolepsy Type 1: Orexin Agonist Restoration Research

Because partial or complete Orexin receptor deficiency plays an important role in the development of EDS, orexin replacement therapy may improve EDS through a pathophysiology-directed mechanism of action. We are currently investigating a new novel drug that acts to help address the deficiency of orexin-2 receptor agonists that may address the spectrum of narcolepsy symptoms and have greater efficacy than currently approved drugs for EDS and cataplexy.

Study Details

• A phase-2, Randomized, double-blind clinical research study
• Participants will last up to approximately 14 weeks with an optional adjusted dose 7 week extension
• All participants will stop narcolepsy symptoms medications for at least 14 days prior to study start day and for the duration of the study.
• 7-9 mandatory visits at our clinic
• 2 mandatory overnight visits at our clinic’s newly renovated sleep lab suites
• Eligible subjects receive compensation for their time and participation

If you are interested in learning more or want to participate, please visit Current Clinical Trials | Intrepid Research (intrepidresearchoh.com)